



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/589,159	08/10/2006	Pratibha Pilgaonkar	11336.0033USWO	6952
23552	7590	02/19/2010	EXAMINER	
MERCHANT & GOULD PC			GREENE, IVAN A	
P.O. BOX 2903			ART UNIT	
MINNEAPOLIS, MN 55402-0903			PAPER NUMBER	
			1619	
			MAIL DATE	
			DELIVERY MODE	
			02/19/2010	
			PAPER	

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

### Office Action Summary

**Application No.**

10/589,159

**Applicant(s)**

PILGAONKAR ET AL.

**Examiner**

IVAN GREENE

**Art Unit**

1619

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 16 October 2009.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-4, 6-9, 14-19, 21-25 and 27-31 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-4, 6-9, 14-19, 21-25 and 27-31 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_

### **DETAILED ACTION**

Claims 1-4, 6-9, 14-19, 21-25 and 27-31 are pending. Claims 5, 10-13, 20, 26 and 32 have been canceled by applicant. Claims 1-4, 6-9, 14-19, 21-25, and 27-31 are presented for examination on the merits.

The effective U.S. filing date of the instant application is 02/10/2005, the filing date of the international application PCT/IB05/00330. The foreign priority date has been determined to be 02/11/2004, the filing date of Australian document 2004900661.

All rejections and/or objections not explicitly maintained in the instant office action have been withdrawn per Applicants' claim amendments and/or persuasive arguments.

#### ***Claim Rejections - 35 USC § 112 - Second Paragraph***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

- 1. Rejection Maintained with respect to claims 18; Claims 18 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.**
- Claim 18 recites the limitation "the hydrophilic polymer" in line 2. There is insufficient antecedent basis for this limitation in the claim. The examiner notes that claims 15, 16 and 17 have been amended to depend from claim 15, however, it appears that applicant has overlooked claim 18. Appropriate correction is required.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

1. **New Grounds of Rejection Necessitated by Amendment: Claims 1-4, 6-9, 14-19 and 21-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over FALK (US 4,803,081) and SHELL (US 5,972,389) in view of PATEL (US 2003/0180352).**
2. **In view of the 35 U.S.C. 112, second paragraph of claim 18, for purposes of examination on the merits claim 18 is being read to depend from claim 15.**

**Applicant claims**

Applicant claims a controlled release oral pharmaceutical composition comprising (a) a therapeutically effective amount of one or more pharmacological agents showing low bioavailability, (b) one or more solubilizers, wherein the ratio of the solubilizer to the drug is about 20:1 to about 1:20, (c) one or more biocompatible swelling agents, and (d)

a swelling enhancer; wherein the swelling agent in combination with swelling enhancer, swell in the presence of gastric fluid such that the size of the dosage form is sufficiently increased to not pass through the pylorus, thereby providing retention of the dosage form in the stomach of a patient. Applicant further claims the controlled release composition swells in the presence of gastric fluid such that the dosage form is retained until it erodes in the stomach of the patient. Applicant further claims the composition comprises an active agent selected from antiarrhythmic, antihypertensive, and antifungal active agents, among others. Applicant further claims the active agent selected from nifedipine, nicardipine, cyclosporine, and digoxin, among others. Applicant further claims the composition wherein the solubilizer is selected from PEG-40 hydrogenated castor oil, among others. Applicant claims a controlled release oral pharmaceutical composition wherein the biocompatible swelling agent is the hydrophilic polymer poly(ethylene oxide). Applicant further claims the controlled release oral pharmaceutical composition wherein the swelling enhancer is cross-linked polyvinylpyrrolidone ([known in the art as crospovidone]).

**Determination of the scope and content  
of the prior art (MPEP 2141.01)**

FALK teaches an extended release preparation of an active compound with very low solubility containing the active compound dissolved or dispersed in a semi-solid or liquid non-ionic solubilizer (abstract). FALK further teaches the object of their invention is to provide a preparation of a drug with very low solubility that shows prolonged and nearly constant rate of drug absorption for a long period of time and concurrently

maintains a high extent of bioavailability (2:67-68; 3:1-3). FALK further teaches the object of their invention is achieved by using a solubilizer which is mixed with the drug with very low solubility (3:3-5). FALK further teaches the active compound is dissolved or dispersed in the solubilizer, and the mixture of drug and solubilizer is incorporated into a pharmaceutical formulation, which gives prolonged release (3:6-7, 14-16). FALK further teaches the example drugs useful in their invention include nifedipine, felodipine, griseofulvin, digoxin, oxazepam, phenytoin and cyclosporine (3:22-24, 30-32). FALK further teaches the preferred solubilizers are polyethoxylated castor oil, polyethoxylated hydrogenated castor oil, polyethoxylated fatty acid from castor oil or polyethoxylated fatty acid from hydrogenated castor oil, commercially available under the trade names Cremophor®, Myrj®, and Polyoxyl® 40 stearate, among others (3:39-47). FALK further teaches (at column 3):

**The active compound mixed with the solubilizer is incorporated into different kinds of known controlled release systems, e.g. a hydrophilic gel system, beads 50 coated with a rate controlling membrane, which can be a diffusion retarding coating or a disintegrating coating or tablets with an inert porous matrix. According to the invention the solubilized drug is preferably combined with a hydrophilic gel system, namely a hydrophilic 55 swelling matrix e.g. HPMC. This form of controlled**

FALK teaches preparations according to the invention have a ratio of active compound to solubilizer ranging from 1:1 to 1:10 (4:18-21). FALK further teaches example 5 consisting of the following ingredients:

Ingredient (function)	amount (g)	percent of total
-----------------------	------------	------------------

Nifedipine (active agent)	20	4.29%
Cremophor® RH 40 (solubilizer)	50	10.70%
HPMC 50 cps (swelling agent)	70	15.00%
HPMC 6 cps (swelling agent)	160	34.30%
microcrystalline cellulose (swelling enhancer)	6	1.29%
Lactose (swelling enhancer)	56	12.02%
Aluminum silicate (filler)	94	20.17%
Sodium stearyl fumarate (lubricant)	10	2.14%

FALK further teaches the composition according to example 5 was formed into hydrophilic matrix tablets containing 20 mg of nifedipine per tablet (6:32-34) From the above table the active agent is the antihypertensive, poorly water soluble drug, nifedipine; the solubilizer is Cremophor® RH 40; the ratio of solubilizer to drug is 5:2; the tablet consist of 49.3% HPMC swelling agents, and 13.3% microcrystalline cellulose/lactose swelling enhancers.

**Ascertainment of the difference between  
the prior art and the claims (MPEP 2141.02)**

The difference between the rejected claims and FALK is that FALK does not expressly teach a gastric retentive dosage form, the swelling agent poly(ethylene oxide) or the swelling enhancer cross-linked polyvinylpyrrolidone.

The deficiency in the swelling agent poly(ethylene oxide) is cured by the teachings of SHELL. And the deficiency in the swelling enhancer cross-linked polyvinylpyrrolidone is cured by the teachings of PATEL.

SHELL teaches a controlled release dosage form comprising a hydrophilic swelling matrix their invention relates to dosage forms that are retained in the stomach and gradually deliver sparingly soluble drugs over a time period of several hours (1:8-12). SHELL further teaches their invention provides swellable polymer systems to deliver drugs into the gastrointestinal tract (1:12-16). SHELL further teaches the preferred embodiment wherein the swellable polymer is poly(ethylene oxide) (7:57-67).

PATEL teaches solid pharmaceutical compositions for improved delivery of active agents (title). PATEL further teaches the exemplary additives that are conventionally used in pharmaceutical compositions ([0236]) including disintegrants or superdisintegrants, such as starch derivatives, cellulose derivatives, crosslinked polyvinylpyrrolidone and microcrystalline cellulose, among others ([0248]).

### **Finding of prima facie obviousness**

#### **Rationale and Motivation (MPEP 2142-2143)**

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made to combine the teachings of SHELL with the teachings of FALK, and produce the instantly claimed invention because they each teach controlled release pharmaceutical dosage forms comprising a hydrophilic swellable matrix. It is prima facie obvious to combine compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose, i.e. a controlled release formulation comprising a hydrophilic swellable matrix (MPEP 2144.06). One of ordinary skill in the



art would have been motivated to combine SHELL with FALK and produce the instantly claimed invention because the poly(ethylene oxide) hydrophilic polymer would have provided an alternative hydrophilic polymer which has already been approved for use as a pharmaceutical excipient.

It would have been *prima facie* obvious at the time the claimed invention was made to use the disintegrant cross-linked polyvinylpyrrolidone, as taught by PATEL, because the cross-linked polyvinylpyrrolidone would have been an obvious variant of the microcrystalline cellulose taught by FALK. One of ordinary skill in the art would have been motivated to use cross-linked polyvinylpyrrolidone because the well known excipient would have provided excellent swelling characteristics for the swellable matrix tablet.

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

In light of the forgoing discussion, the Examiner concludes that the subject matter defined by the instant claims would have been obvious within the meaning of 35 USC 103(a).

**Response to Arguments:**

Applicant's arguments filed 10/16/2009 have been fully considered but they are not persuasive.

Applicant's argument that the invention of FALK discloses that the major part of the hydrophilic gel system has a viscosity below 100 cps [and thus] cannot lead to retention of the dosage form in the stomach, is not convincing because FALK clearly teaches that:

**The active compound mixed with the solubilizer is incorporated into different kinds of known controlled release systems, e.g. a hydrophilic gel system, beads 50**

therefore, it would have been obvious to simply take the drug and solubilizer combination and included it in another controlled release dosage form, such as the one taught by SHELL. Furthermore, it is noted that applicant's assertion that the dosage form [of FALK] "cannot lead to retention of the dosage form in the stomach" is not supported by evidence, and the viscosity of the dosage form is not a limitation of the instantly recited claims.

Applicant's assertion that "Falk et al. reference fails to teach or suggest any inventive features of the presently claimed invention" is acknowledged. The examiner respectfully disagrees, FALK clearly teaches the combination of an active agent showing low bioavailability with one or more solubilizers. FALK further teaches the use of the active agent/solubilizer combination in different types of dosage forms such as hydrophilic swelling matrix type dosage forms (3:55-56).

Applicant's argument that the dosage form of SHELL is a multiparticulate type of a gastroretentive system and not a monolithic or multilayered matrix type of gastroretentive system is not convincing because the instantly rejected claims do not require "a monolithic [...] type" formulation. And the claims (27-31) which recite a multi-

layered formulation are not rejected over SHELL. Finally the independent claim does not require any specific amount of time that the dosage form should be retained in the stomach for, and SHELL teaches dosage forms that are retained in the stomach and gradually deliver sparingly soluble drugs over a time period of several hours (1:8-12), e.g. 6 to 8 hours (5:28-32; i.e. up to about 12 hours).

Applicant's assertion that PATEL does not disclose or suggest a gastroretentive system and provides no specificity of use regarding the disclosed cross-linked polyvinyl pyrrolidone is acknowledged. In response the examiner argues that the disclosed cross-linked polyvinylpyrrolidone as a disintegrant and a person having ordinary skill in the art would have known how to employ the conventionally used ingredient crosslinked polyvinylpyrrolidone in a dosage form such as that taught by SHELL.

**3. Claims 27-31 remain rejected under 35 U.S.C. 103(a) as being unpatentable over FALK (US 4,803,081) in view of DOSHI (US 2003/0232081).**

#### **Applicant claims**

Applicant claims a pharmaceutical dosage form in the form of an expanding multi-layered system comprising a first layer property having at least one active pharmaceutical ingredient with an immediate release property; and a second layer having at least one active pharmaceutical ingredient with a sustained release property, one or more solubilizers, one or more biocompatible swelling agents and a swelling enhancer. Applicant further claims the pharmaceutical dosage form wherein the first layer comprises a disintegrating agent selected from starch, sodium starch glycolate, cross-linked polyvinylpyrrolidone, among others. Applicant further claims a method for

preparing a pharmaceutical dosage form comprising the steps of solubilizing an active pharmaceutical ingredient and incorporating said solubilized active agent in a gastro retentive matrix having one or more swelling agents and one or more swelling enhancers.

**Determination of the scope and  
content of the prior art (MPEP 2141.01)**

FALK teaches an extended release preparation of an active compound with very low solubility containing the active compound dissolved or dispersed in a semi-solid or liquid non-ionic solubilizer, as discussed above. FALK further teaches in example 1: felodipine was dissolved in Cremophor® RH 40 and the solution obtained was carefully mixed with the carrier materials, HPMC, xanthan gum, guar gum, and calcium phosphate (5:14-17).

**Ascertainment of the difference between  
the prior art and the claims (MPEP 2141.02)**

The difference between the rejected claims and FALK is that FALK does not teach a multi-layered expanding gastric retentive dosage form or the swelling enhancer cross-linked polyvinylpyrrolidone.

The deficiencies in a multi-layered expanding gastric retentive dosage form and the swelling enhancer cross-linked polyvinylpyrrolidone are cured by the teachings of DOSHI.

DOSHI teaches a floating bilayer tablet which is retained in the stomach of the patient (col. 3, lines 65-67; col. 4 lines 1-4; as discussed above). DOSHI further teaches

the pharmaceutical bilayer composition of their invention is effective for immediate release of active agent from one layer followed by continuous, controlled delivery of active agent present in the second layer, and the active agent in the first and second layers may be the same or different (4:28-35). DOSHI further teaches the pharmaceutical compositions of the present invention can also comprise well known ingredients such as disintegrants, povidone [cross-linked polyvinylpyrrolidone], microcrystalline cellulose, sodium starch glycolate, and starch, among others (7:13-14, 24, 28-29, 32).

#### **Finding of *prima facie* obviousness**

##### **Rationale and Motivation (MPEP 2142-2143)**

It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to combine the teachings of DOSHI with the teachings of FALK, and produce the instant invention because the bilayer system of DOSHI would lead to an improved pharmaceutical product, one with instant and sustained release layers. One of ordinary skill in the art would have been motivated to combine DOSHI with FALK and produce a bilayer dosage form with instant release and continuous release properties because the immediate release layer would provide for a faster onset of drug action.

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole would have been *prima facie* obvious to

one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

In light of the forgoing discussion, the Examiner concludes that the subject matter defined by the instant claims would have been obvious within the meaning of 35 USC 103(a).

**Response to Arguments:**

Applicant's arguments filed 10/16/2009 have been fully considered but they are not persuasive.

Applicant's argument that the invention of DOSHI relies on swelling plus gas generation for imparting buoyancy to the dosage form and is therefore unlike compositions of the present invention is not convincing because the instantly rejected claims recite --an expanding multi-layered system-- and do not delineate among expanding dosage forms. Applicant is respectfully reminded that during examination it is improper to import claim limitations from the specification (MPEP § 2111.01).

Applicant's argument that DOSHI does not in any manner disclose or suggest systems that can achieve gastroretention by relying on a single mechanism is acknowledged. In response to applicant's argument that the references fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., "gastroretention by relying on a single mechanism") are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

***Conclusion***

Claims 1-4, 6-9, 14-19, 21-25, and 27-31 have been examined on the merits. Claim 18 is rejected under 35 U.S.C. 112, second paragraph; claims 1-4, 6-9, 14-19, 21-25, and 27-31 are rejected under 35 U.S.C. 103(a). No claims allowed at this time.

**THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **IVAN GREENE** whose telephone number is (571)270-5868. The examiner can normally be reached on Monday through Thursday 7AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bonnie Eyler can be reached on (571) 272-0871. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/YVONNE L. EYLER/  
Supervisory Patent Examiner, Art Unit 1619

IVAN GREENE  
Examiner, Art Unit 1619